GXYLT1

Across TCGA pan-cancer cohorts, GXYLT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GXYLT1 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GXYLT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GXYLT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where GXYLT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.369	0.833	<.001	89	view →
LUAD	OS	Median	III,IV	0.354	0.882	.016	8	view →
HNSC	DFS	Quartile	All	0.205	0.860	.024	6	view →
PDAC	OS	Median	III,IV	0.611	0.188	.040	2	view →
GBM	OS	Tertile	All	0.730	0.917	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GXYLT1–CCRCC (DFS)

Open the CCRCC breakdown →